Format

Send to

Choose Destination
Cancer Chemother Pharmacol. 2009 Dec;65(1):67-71. doi: 10.1007/s00280-009-1003-z. Epub 2009 May 7.

Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.

Author information

1
Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, 1429 First Avenue at 74th Street, New York, NY 10021, USA. cassileth@mskcc.org

Abstract

PURPOSE:

To study a commonly used Astragalus-based herbal formula previously found effective in non-small cell lung cancer (NSCLC) on the pharmacokinetics of docetaxel in patients with NSCLC.

METHODS:

Patients with advanced NSCLC who progressed after prior platinum-containing chemotherapy were accrued and received docetaxel at 35 mg/m(2) for 3 weeks followed by 1 week of rest. At 4 days prior to the second dosing, Jinfukang was given orally. Pharmacokinetic studies of initial-dose docetaxel (in the absence of Jinfukang) and the third dose (in the presence of Jinfukang) were compared.

RESULTS:

Of the 24 patients enrolled, 21 started Jinfukang and docetaxel. Jinfukang had no significant impact on the pharmacokinetics of docetaxel. Median time to progression or withdrawal from treatment was 7 weeks. Twelve patients were removed from study for progression of disease; nine patients withdrew.

CONCLUSIONS:

Jinfukang did not alter the pharmacokinetics of docetaxel nor appear to affect survival in this study.

PMID:
19421753
PMCID:
PMC3746541
DOI:
10.1007/s00280-009-1003-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center